Next Article in Journal
Highly Effective mRNA-LNP Vaccine Against Respiratory Syncytial Virus (RSV) in Multiple Models
Previous Article in Journal
Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign
Previous Article in Special Issue
Vaccinating in Different Settings: Best Practices from Italian Regions
 
 
Systematic Review

Article Versions Notes

Vaccines 2025, 13(6), 624; https://doi.org/10.3390/vaccines13060624
Action Date Notes Link
article xml file uploaded 10 June 2025 08:02 CEST Original file -
article xml uploaded. 10 June 2025 08:02 CEST Update -
article pdf uploaded. 10 June 2025 08:02 CEST Version of Record -
article xml file uploaded 10 June 2025 08:13 CEST Update -
article xml uploaded. 10 June 2025 08:13 CEST Update https://www.mdpi.com/2076-393X/13/6/624/xml
article pdf uploaded. 10 June 2025 08:13 CEST Updated version of record https://www.mdpi.com/2076-393X/13/6/624/pdf
article html file updated 10 June 2025 08:17 CEST Original file -
article html file updated 10 June 2025 08:21 CEST Update -
article html file updated 25 June 2025 08:53 CEST Update https://www.mdpi.com/2076-393X/13/6/624/html
Back to TopTop